Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Enanta Pharmaceuticals Inc's Business Segments
Enanta Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Royalty
Total Revenue
$ 14
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Royalty0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 50 | - |
Revenue by Product & Service Category - FY
- Royalty100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 17 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Royalty0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 50 | - |
Description of Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc is a biotechnology company that specializes in developing small molecule drugs for infectious diseases, liver diseases, and cancer. The company was founded in 1995 and is located in Watertown, Massachusetts.
Enanta’s main focus is on developing antiviral drugs for the treatment of hepatitis C virus (HCV) and respiratory syncytial virus (RSV). The company’s lead product, paritaprevir, is a protease inhibitor used in combination with other drugs to treat patients with chronic HCV infection. Paritaprevir is sold under the brand name VIEKIRA PAK by AbbVie Inc.
In addition to paritaprevir, Enanta has several other drugs in its pipeline for the treatment of HCV, such as EDP-514, a non-nucleoside polymerase inhibitor, and EDP-305, a farnesoid X receptor agonist.
Aside from HCV, Enanta is also developing drugs for RSV, a virus that causes respiratory infections in infants and older adults. The company’s lead RSV asset, EDP-938, is an orally bioavailable fusion inhibitor that is designed to prevent the virus from entering human cells. Enanta is currently conducting Phase 2a clinical trials on EDP-938.
Aside from its antiviral programs, Enanta is also developing drugs for the treatment of non-alcoholic steatohepatitis (NASH), a liver disease that is closely associated with obesity and diabetes. Enanta’s lead NASH asset, EDP-305, is a farnesoid X receptor agonist that is designed to reduce liver inflammation and fibrosis. Enanta is currently conducting a Phase 2a clinical trial on EDP-30
Enanta has established collaborations with several major pharmaceutical companies, including AbbVie, Novartis, and Gilead Sciences. These collaborations provide the company with funding and expertise to advance its drug development programs.
Enanta Pharmaceuticals Inc has received numerous awards and recognitions for its drug development efforts, including the 2015 Technology of the Year Award by the Massachusetts Technology Leadership Council and the 2016 Biotech Pioneer Award by the Boston Business Journal.
Enanta’s main focus is on developing antiviral drugs for the treatment of hepatitis C virus (HCV) and respiratory syncytial virus (RSV). The company’s lead product, paritaprevir, is a protease inhibitor used in combination with other drugs to treat patients with chronic HCV infection. Paritaprevir is sold under the brand name VIEKIRA PAK by AbbVie Inc.
In addition to paritaprevir, Enanta has several other drugs in its pipeline for the treatment of HCV, such as EDP-514, a non-nucleoside polymerase inhibitor, and EDP-305, a farnesoid X receptor agonist.
Aside from HCV, Enanta is also developing drugs for RSV, a virus that causes respiratory infections in infants and older adults. The company’s lead RSV asset, EDP-938, is an orally bioavailable fusion inhibitor that is designed to prevent the virus from entering human cells. Enanta is currently conducting Phase 2a clinical trials on EDP-938.
Aside from its antiviral programs, Enanta is also developing drugs for the treatment of non-alcoholic steatohepatitis (NASH), a liver disease that is closely associated with obesity and diabetes. Enanta’s lead NASH asset, EDP-305, is a farnesoid X receptor agonist that is designed to reduce liver inflammation and fibrosis. Enanta is currently conducting a Phase 2a clinical trial on EDP-30
Enanta has established collaborations with several major pharmaceutical companies, including AbbVie, Novartis, and Gilead Sciences. These collaborations provide the company with funding and expertise to advance its drug development programs.
Enanta Pharmaceuticals Inc has received numerous awards and recognitions for its drug development efforts, including the 2015 Technology of the Year Award by the Massachusetts Technology Leadership Council and the 2016 Biotech Pioneer Award by the Boston Business Journal.
Enanta Pharmaceuticals Inc. is a biotechnology company with a strong emphasis on research and development in the field of small molecule drugs, specifically targeting viral infections and liver diseases. Based in Massachusetts, the company is committed to innovation in the pharmaceuticals industry via its various segments, products, and services.
Segments
1. Infectious Disease Segment:
Enanta Pharmaceuticals has a core focus on the discovery and development of therapeutics for infectious diseases, especially those that are severe and life-threatening. Key areas of interest in this segment include:
- Respiratory Syncytial Virus (RSV): Enanta is actively engaged in developing antiviral therapies for RSV, which is a major cause of respiratory infections in infants and the elderly.
- Hepatitis B Virus (HBV): The company is exploring treatments for individuals with chronic HBV infections, aiming to improve outcomes and control viral replication.
- Hepatitis C Virus (HCV): Enanta has made significant strides in developing protease inhibitors specifically designed to treat HCV, contributing to the evolution of treatment regimens for this viral infection.
- Human Immunodeficiency Virus (HIV): Through innovative research, Enanta is also developing compounds to treat HIV, striving for improved efficacy and reduced side effects for patients living with this virus.
2. Non-Alcoholic Steatohepatitis (NASH):
This segment is dedicated to addressing the needs of patients suffering from NASH, a progressive liver disease characterized by fat accumulation, inflammation, and damage not caused by alcohol consumption. Enanta’s focus includes:
- Identifying and developing drugs that can mitigate liver inflammation, promote fat metabolism, and ultimately halt or reverse disease progression.
- Use of small molecule therapies targeting specific pathways, such as the farnesoid X receptor (FXR), which play a crucial role in liver pathology associated with NASH.
Products
1. Antiviral Drugs:
Enanta has developed a portfolio of antiviral agents designed to target specific viral infections. Notable products include:
- NUC Inhibitors: These small molecules are aimed at treating chronic HBV infections, providing patients with a means to control viral replication effectively.
- Protease Inhibitors: Developed for the treatment of HCV, these inhibitors function by blocking essential viral enzymes, thereby preventing the virus from replicating.
- Nucleoside Inhibitors: Enantas nucleoside inhibitors target a range of viral infections, offering broad-spectrum antiviral activity.
2. FXR Agonists:
This class of products is pivotal in the management of NASH. FXR agonists activate the farnesoid X receptor, which influences several metabolic pathways in the liver. These include:
- Reducing hepatic triglyceride levels,
- Decreasing liver inflammation,
- Promoting bile acid homeostasis.
Services
1. Contract Research:
Enanta offers contract research services that extend its expertise to other pharmaceutical and biotechnology enterprises. Services include:
- Drug Discovery: Utilizing cutting-edge techniques and thorough research to identify new drug candidates.
- Drug Design: Tailored medicinal chemistry solutions to optimize the properties of drug candidates.
- Preclinical Testing: Comprehensive preclinical analysis to assess the safety and efficacy of new compounds before they enter clinical trials.
- Clinical Trials: Providing logistical and regulatory support to facilitate the advancement of drug candidates through pivotal clinical trials.
2. Licensing Partnerships:
To expand the impact of its innovative therapies, Enanta forms strategic licensing partnerships with other pharmaceutical companies. This includes:
- Licensing agreements for the development and commercialization of its antiviral agents and FXR agonists.
- Collaborative agreements that allow partners to leverage Enanta’s research capabilities and intellectual property.
Conclusion
In summary, Enanta Pharmaceuticals Inc. stands at the forefront of biotechnology with a robust pipeline focused on treating infectious diseases and liver-related conditions. Its commitment to research and development, alongside its offerings of antiviral drugs and FXR agonists, positions it as a key player in providing innovative therapeutic solutions and advanced research services within the pharmaceutical industry. Through concerted efforts in contract research and strategic licensing, Enanta contributes to the ongoing fight against viral infections and the management of liver diseases, catering to a significant segment of the patient population affected by these conditions.
Segments
1. Infectious Disease Segment:
Enanta Pharmaceuticals has a core focus on the discovery and development of therapeutics for infectious diseases, especially those that are severe and life-threatening. Key areas of interest in this segment include:
- Respiratory Syncytial Virus (RSV): Enanta is actively engaged in developing antiviral therapies for RSV, which is a major cause of respiratory infections in infants and the elderly.
- Hepatitis B Virus (HBV): The company is exploring treatments for individuals with chronic HBV infections, aiming to improve outcomes and control viral replication.
- Hepatitis C Virus (HCV): Enanta has made significant strides in developing protease inhibitors specifically designed to treat HCV, contributing to the evolution of treatment regimens for this viral infection.
- Human Immunodeficiency Virus (HIV): Through innovative research, Enanta is also developing compounds to treat HIV, striving for improved efficacy and reduced side effects for patients living with this virus.
2. Non-Alcoholic Steatohepatitis (NASH):
This segment is dedicated to addressing the needs of patients suffering from NASH, a progressive liver disease characterized by fat accumulation, inflammation, and damage not caused by alcohol consumption. Enanta’s focus includes:
- Identifying and developing drugs that can mitigate liver inflammation, promote fat metabolism, and ultimately halt or reverse disease progression.
- Use of small molecule therapies targeting specific pathways, such as the farnesoid X receptor (FXR), which play a crucial role in liver pathology associated with NASH.
Products
1. Antiviral Drugs:
Enanta has developed a portfolio of antiviral agents designed to target specific viral infections. Notable products include:
- NUC Inhibitors: These small molecules are aimed at treating chronic HBV infections, providing patients with a means to control viral replication effectively.
- Protease Inhibitors: Developed for the treatment of HCV, these inhibitors function by blocking essential viral enzymes, thereby preventing the virus from replicating.
- Nucleoside Inhibitors: Enantas nucleoside inhibitors target a range of viral infections, offering broad-spectrum antiviral activity.
2. FXR Agonists:
This class of products is pivotal in the management of NASH. FXR agonists activate the farnesoid X receptor, which influences several metabolic pathways in the liver. These include:
- Reducing hepatic triglyceride levels,
- Decreasing liver inflammation,
- Promoting bile acid homeostasis.
Services
1. Contract Research:
Enanta offers contract research services that extend its expertise to other pharmaceutical and biotechnology enterprises. Services include:
- Drug Discovery: Utilizing cutting-edge techniques and thorough research to identify new drug candidates.
- Drug Design: Tailored medicinal chemistry solutions to optimize the properties of drug candidates.
- Preclinical Testing: Comprehensive preclinical analysis to assess the safety and efficacy of new compounds before they enter clinical trials.
- Clinical Trials: Providing logistical and regulatory support to facilitate the advancement of drug candidates through pivotal clinical trials.
2. Licensing Partnerships:
To expand the impact of its innovative therapies, Enanta forms strategic licensing partnerships with other pharmaceutical companies. This includes:
- Licensing agreements for the development and commercialization of its antiviral agents and FXR agonists.
- Collaborative agreements that allow partners to leverage Enanta’s research capabilities and intellectual property.
Conclusion
In summary, Enanta Pharmaceuticals Inc. stands at the forefront of biotechnology with a robust pipeline focused on treating infectious diseases and liver-related conditions. Its commitment to research and development, alongside its offerings of antiviral drugs and FXR agonists, positions it as a key player in providing innovative therapeutic solutions and advanced research services within the pharmaceutical industry. Through concerted efforts in contract research and strategic licensing, Enanta contributes to the ongoing fight against viral infections and the management of liver diseases, catering to a significant segment of the patient population affected by these conditions.